RxDoctor Payments Data

Jeffrey Arnold

Nurse Practitioner · Westwego, LANPI 1477512705

Payments from drug & device makers

$983in general payments, 2019–2025

Across 44 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$179
  • Novo Nordisk$153
  • Dexcom, Inc.$109
  • Lilly USA, LLC$103
  • Pfizer$71
  • Exact Sciences$67
  • plus $301 from 10 others

What the payments were for

  • Food & beverage$983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$983 in reported general payments places this provider in the 65th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$22,316
Medicare patients
206
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$34,067
OzempicSemaglutide22$22,358
JanuviaSitagliptin Phosphate16$21,314
XareltoRivaroxaban17$14,290
JardianceEmpagliflozin17$11,411
Albuterol Sulfate HfaAlbuterol Sulfate41$1,282
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$794
Atorvastatin Calcium93$762
SynthroidLevothyroxine Sodium16$754
Pantoprazole Sodium65$732
Gabapentin67$569
Fluticasone Propionate50$538
Esomeprazole Magnesium23$536
Duloxetine Hcl41$535
Pravastatin Sodium31$466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$34,06734 claims
Novo NordiskOzempic$153$22,35822 claims
MerckJanuvia$30$21,31416 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$40442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Westwego

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →